Effect of acenocoumarine on the breast-fed infant.
Apart from teratogenic phenomena and the potential risk of maternal or neonatal peripartum haemorrhage, the use of oral anticoagulants during pregnancy poses an additional hazard: the risk of transferring some anticoagulant activity to the nursing infant through breast milk. We analysed the coagulation status of seven full term breast-fed neonates whose mothers were under chronic anticoagulant therapy with acenocoumarine as thromboembolic prophylaxis following cardiac valve replacement. Prothrombin Times (PT) observed in neonates were significantly higher than the corresponding maternal values. Data were subsequently compared with those obtained from a control group comprising forty-two full term neonates nursed by non-anticoagulated mothers: coagulation profiles again showed no signs of any noticeable antivitamin K effect. Our results indicate that mothers given acenocoumarine at therapeutic doses may safely breast-feed their infants: anticoagulant activity in breast milk seems to be negligible as assessed by neonates PT.
Fondevila
C G
CG
Department of Hemostasis and Thrombosis, Instituto de Investigaciones Hematologicas Mariano R. Castex Buenos Aires, Argentina.
Meschengieser
S
S
Blanco
A
A
Peñalva
L
L
Lazzari
M A
MA
D000074:Acenocoumarol / Q000009:adverse effects*; D000293:Adolescent; D000328:Adult; D001942:Breast Feeding; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011247:Pregnancy; D011517:Prothrombin Time; D014812:Vitamin K / Q000494:pharmacology
D014812:Vitamin K; D000074:Acenocoumarol